当前位置: X-MOL 学术Biom. J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction
Biometrical Journal ( IF 1.3 ) Pub Date : 2021-06-04 , DOI: 10.1002/bimj.202170054


April 23, 2021

Dear Editors,

Biometrical Journal

In the paper by Fujikawa et al. entitled “A Bayesian basket-trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability” published in 2020, Biometrical Journal, 62, 330–338, DOI: 10.1002/bimj.201800404, we wish to correct the following:

(i) Table 1

TABLE 1. Posterior probabilities for the basket trial of the BRAF inhibitor vemurafenib for three cases
NSCLC Colorectal vemurafinib Colorectal vemurafinib cetuximab Cholangio ECD or LCH Anaplastic thyroid carcinoma Glioma MM PXA Other
No. of responders/No. of observations 8/19 0/10 1/26 1/8 6/14 2/7 0/8 0/5 3/4 3/14

Case (i):

Independent analysis

0.76 0.01 <0.01 0.12 0.75 0.43 0.02 0.08 0.95 0.17

Case (ii):

Borrowing-information analysis based on proposed design

0.80 <0.01 <0.01 <0.01 0.80 0.37 <0.01 <0.01 0.92 0.15

Case (iii):

Borrowing-information analysis based on Simon's design

0.95 0.03 <0.01 0.15 0.90 0.41 0.05 0.11 0.82 0.24
  • NSCLC, nonsmall cell lung cancer; ECD, Erdheim-Chester disease; LCH, Langerhans cell histiocytosis; MM, multiple myeloma; PXA, pleomorphic xanthoastrocytoma.

(ii) The fifth sentence in the section 3 of “The posterior probabilities for the borrowing-information analysis based on our design (case (ii)) were larger than those for the independent analysis (case (i)) for NSCLC, ECD or LCH, anaplastic thyroid carcinoma, and much smaller than”

The revised text is as follows:

“The posterior probabilities for the borrowing-information analysis based on our design (case (ii)) were larger than those for the independent analysis (Case (i)) for NSCLC, ECD or LCH, and much smaller than”

(iii) A submitted R code “Table _1.R”

We have attached the revised R code “Table_1.R” (as Supporting Information).

The correct Table 1 is as given below.

We have corrected the probabilities for Case (ii) for NSCLC, ECD or LCH, Anaplastic thyroid carcinoma, and Other.

Sincerely,

Satoshi Teramukai

Department of Biostatistics

Graduate School of Medical Science

Kyoto Prefectural University of Medicine



中文翻译:

更正

2021 年 4 月 23 日

亲爱的编辑们,

生物识别杂志

在 Fujikawa 等人的论文中。题为“基于响应概率的后验分布之间的相似性跨层借用信息的贝叶斯篮式试验设计”,发表于 2020 年,Biometrical Journal,62, 330–338,DOI:10.1002/bimj.201800404,我们希望更正以下内容:

(一) 表 1

表 1. BRAF 抑制剂 vemurafenib 篮子试验三个病例的后验概率
非小细胞肺癌 结直肠vemurafinib 大肠威罗非尼西妥昔单抗 乔拉焦 ECD 或 LCH 甲状腺未分化癌 胶质瘤 毫米 PXA 其他
响应者数量/数量 观察结果 8/19 0/10 1/26 1/8 6/14 2/7 0/8 0/5 3/4 3/14

情况(一):

独立分析

0.76 0.01 <0.01 0.12 0.75 0.43 0.02 0.08 0.95 0.17

情况(二):

基于提议设计的借款信息分析

0.80 <0.01 <0.01 <0.01 0.80 0.37 <0.01 <0.01 0.92 0.15

情况(三):

基于西蒙设计的借款信息分析

0.95 0.03 <0.01 0.15 0.90 0.41 0.05 0.11 0.82 0.24
  • NSCLC,非小细胞肺癌;ECD,Erdheim-Chester 病;LCH,朗格汉斯细胞组织细胞增生症;MM,多发性骨髓瘤;PXA,多形性黄色星形细胞瘤。

(ii) “基于我们的设计的借用信息分析的后验概率(案例(ii))大于非小细胞肺癌、ECD 或独立分析(案例(i))的后验概率”的第 3 节中的第五句。 LCH,甲状腺未分化癌,远小于“

修改后的文本如下:

“基于我们的设计(案例(ii))的借用信息分析的后验概率大于非小细胞肺癌、ECD 或 LCH 的独立分析(案例(i))的后验概率,远小于”

(iii) 提交的 R 代码“表_1.R”

我们附上了修订后的 R 代码“Table_1.R”(作为支持信息)。

正确的表 1 如下所示。

我们已经更正了 NSCLC、ECD 或 LCH、甲状腺未分化癌和其他病例 (ii) 的概率。

真挚地,

照会聪

生物统计学系

医学研究生院

京都府立医科大学

更新日期:2021-06-04
down
wechat
bug